Takeda Pharmaceutical Company Limited delivered solid FY2025 results that demonstrate the resilience and earnings power of its business model. Revenue of Y4464.6B and net income of Y112.9B reflect the company's sustained competitive advantages across its core Drug Manufacturers - Specialty & Generic
Access the complete analysis, financial model, price target breakdown, and risk factors.
Read Full Report →2 free reads per day · No credit card required